Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos' most advanced novel mode-of-action program, was discovered using the Company's proprietary target discovery technology, and is being developed by us in Phase 3 in rheumatoid arthritis. Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas.
Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ; all with the ticker symbol GLPG.
We have a strong investor base, with a long term commitment to the biotech industry. Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website.